Test Verification and Validation for Molecular Diagnostic Assays

被引:33
作者
Halling, Kevin C. [2 ]
Schrijver, Iris [3 ]
Persons, Diane L. [1 ]
机构
[1] Univ Kansas, Dept Pathol & Lab Med, Med Ctr, Kansas City, KS 66160 USA
[2] Mayo Fdn, Dept Lab Med, Rochester, MN USA
[3] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.5858/arpa.2011-0212-ED
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
With our ever-increasing understanding of the molecular basis of disease, clinical laboratories are implementing a variety of molecular diagnostic tests to aid in the diagnosis of hereditary disorders, detection and monitoring of cancer, determination of prognosis and guidance for cancer therapy, and detection and monitoring of infectious diseases. Before introducing any new test into the clinical laboratory, the performance characteristics of the assay must be "verified," if it is a US Food and Drug Administration (FDA)-approved or FDA-cleared test, or "validated," if it is a laboratory-developed test. Although guidelines exist for how validation and verification studies may be addressed for molecular assays, the specific details of the approach used by individual laboratories is rarely published. Many laboratories, especially those introducing new types of molecular assays, would welcome additional guidance, especially in the form of specific examples, on the process of preparing a new molecular assay for clinical use. (Arch Pathol Lab Med. 2012; 136: 11-13; doi: 10.5858/arpa.2011-0212-ED)
引用
收藏
页码:11 / 13
页数:3
相关论文
共 1 条
[1]  
Jennings L, 2009, ARCH PATHOL LAB MED, V133, P743, DOI 10.1043/1543-2165-133.5.743